EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Implementing PEN‐FAST for penicillin allergy delabeling in a high‐prevalence population

Deniz Göcebe iD, Katharina S Kommoss iD, Martin Hartmann, Alexander H Enk, Knut Schäkel

JDDG: Journal der Deutschen Dermatologischen Gesellschaft · 2026

DOI: 10.1111/ddg.15862 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2026. Verfasst von Deniz Göcebe und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany. Hauptthemen laut MEDLINE: Penicillins, Drug Hypersensitivity, Skin Tests, Anti-Bacterial Agents. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and objectives Self‐reported penicillin allergies lead to the use of broad‐spectrum antibiotics, increase drug resistance, and constitute an economic burden. The PEN‐FAST score aims to identify low‐risk patients for direct drug provocation tests (DPT) without prior skin testing with a reported negative predictive value (NPV) of over 95%. Patients and methods In this single‐center study (Department of Dermatology, University Hospital Heidelberg, Germany), the PEN‐FAST score was evaluated for patients carrying a penicillin allergy label between 2004 and 2024. Skin testing, allergen‐specific IgE, and consecutive DPT were performed.

Results

A total of 189 patients were analyzed. In a retrospective cohort, 106 of 149 patients showed negative skin tests and received DPT, leading to the delabeling of 99 patients (66.4%). PEN‐FAST identified 55 of 149 (36.9%) as low‐risk, of which three low‐risk patients were misclassified. In a prospective PEN‐FAST low‐risk cohort, one of 40 patients showed a mild reaction after DPT. Overall, NPVs of both PEN‐FAST and formal allergy testing were 95.8%.

Conclusions

Our results advocate for direct DPT in patients carrying a penicillin allergy label classified as low‐risk by PEN‐FAST. PEN‐FAST demonstrated high NPV, safety, and feasibility in a cohort with a high prevalence of true allergies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PenicillinsDrug HypersensitivitySkin TestsAnti-Bacterial AgentsHumansMaleFemaleMiddle AgedAdultRetrospective StudiesPrevalenceAgedGermanyYoung AdultImmunoglobulin E

Stichwörter der Autor:innen

Allergy delabelingPEN‐FASTdrug allergypenicillin allergy

Substanzen

PenicillinsAnti-Bacterial AgentsImmunoglobulin E

Autor:innen und Institutionen

  • Department of Dermatology, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.
  • Division of Infectious Diseases and Tropical Medicine, University Hospital Heidelberg, Heidelberg University, Heidelberg, Germany.

ORCID-Profile: Deniz Göcebe, Katharina S Kommoss

Zitieren

APA

Göcebe, D., Kommoss, K. S., Hartmann, M., Enk, A. H., & Schäkel, K. (2026). Implementing PEN‐FAST for penicillin allergy delabeling in a high‐prevalence population. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. https://doi.org/10.1111/ddg.15862

Vancouver

Göcebe D, Kommoss KS, Hartmann M, Enk AH, Schäkel K. Implementing PEN‐FAST for penicillin allergy delabeling in a high‐prevalence population. JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 2026. doi:10.1111/ddg.15862

BibTeX
@article{Gcebe2026,
  author = {Göcebe, Deniz and Kommoss, Katharina S and Hartmann, Martin and Enk, Alexander H and Schäkel, Knut},
  title = {Implementing PEN‐FAST for penicillin allergy delabeling in a high‐prevalence population},
  journal = {JDDG: Journal der Deutschen Dermatologischen Gesellschaft},
  year = {2026},
  doi = {10.1111/ddg.15862}
}
Kostenlos starten →